

Thomas J Cradick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6458151/publications.pdf>

Version: 2024-02-01

34
papers

7,342
citations

331670
21
h-index

414414
32
g-index

34
all docs

34
docs citations

34
times ranked

11681
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA targeting specificity of RNA-guided Cas9 nucleases. <i>Nature Biotechnology</i> , 2013, 31, 827-832.	17.5	3,953
2	CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. <i>Nucleic Acids Research</i> , 2014, 42, 7473-7485.	14.5	548
3	CRISPR/Cas9 systems targeting β -globin and CCR5 genes have substantial off-target activity. <i>Nucleic Acids Research</i> , 2013, 41, 9584-9592.	14.5	544
4	COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e214.	5.1	315
5	Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5 Δ 32 mutation confers resistance to HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9591-9596.	7.1	296
6	<i>Streptococcus thermophilus</i> CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome. <i>Molecular Therapy</i> , 2016, 24, 636-644.	8.2	204
7	The <i>Neisseria meningitidis</i> CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells. <i>Molecular Therapy</i> , 2016, 24, 645-654.	8.2	190
8	TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. <i>Nucleic Acids Research</i> , 2014, 42, 6762-6773.	14.5	165
9	Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAs. <i>Molecular Therapy</i> , 2010, 18, 947-954.	8.2	162
10	Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. <i>Nucleic Acids Research</i> , 2012, 40, 5560-5568.	14.5	160
11	Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β -globin locus. <i>Blood</i> , 2018, 131, 1960-1973.	1.4	156
12	An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. <i>Nucleic Acids Research</i> , 2014, 42, e42-e42.	14.5	109
13	Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. <i>Molecular Therapy</i> , 2016, 24, 475-487.	8.2	100
14	A Burden of Rare Variants Associated with Extremes of Gene Expression in Human Peripheral Blood. <i>American Journal of Human Genetics</i> , 2016, 98, 299-309.	6.2	84
15	Defining critical residues in the epitope for a hiv-neutralizing monoclonal antibody using phage display and peptide array technologies. <i>Gene</i> , 1993, 137, 63-68.	2.2	51
16	SAPTA: a new design tool for improving TALE nuclease activity. <i>Nucleic Acids Research</i> , 2014, 42, e47-e47.	14.5	49
17	Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. <i>PLoS ONE</i> , 2015, 10, e0133373.	2.5	46
18	ZFN-Site searches genomes for zinc finger nuclease target sites and off-target sites. <i>BMC Bioinformatics</i> , 2011, 12, 152.	2.6	38

#	ARTICLE	IF	CITATIONS
19	TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e273.	5.1	38
20	Evaluation of Homology-Independent CRISPR-Cas9 Off-Target Assessment Methods. <i>CRISPR Journal</i> , 2020, 3, 440-453.	2.9	32
21	Nanomedicine: Tiny Particles and Machines Give Huge Gains. <i>Annals of Biomedical Engineering</i> , 2014, 42, 243-259.	2.5	26
22	Engineering imaging probes and molecular machines for nanomedicine. <i>Science China Life Sciences</i> , 2012, 55, 843-861.	4.9	13
23	High-Throughput Cellular Screening of Engineered Nuclease Activity Using the Single-Strand Annealing Assay and Luciferase Reporter. <i>Methods in Molecular Biology</i> , 2014, 1114, 339-352.	0.9	13
24	InÂvivo genome editing at the albumin locus to treat methylmalonic acidemia. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 619-632.	4.1	10
25	Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and In Vivo from a Single Lentiviral Vector. <i>Current Gene Therapy</i> , 2014, 14, 365-376.	2.0	8
26	Controlling gene expression in Drosophila using engineered zinc finger protein transcription factors. <i>Biochemical and Biophysical Research Communications</i> , 2006, 348, 873-879.	2.1	7
27	Designing and Testing the Activities of TAL Effector Nucleases. <i>Methods in Molecular Biology</i> , 2014, 1114, 203-219.	0.9	6
28	Identification of Off-Target Cleavage Sites of Zinc Finger Nucleases and TAL Effector Nucleases Using Predictive Models. <i>Methods in Molecular Biology</i> , 2014, 1114, 371-383.	0.9	5
29	331. Development of Neisseria meningitidis CRISPR/Cas9 Systems for Efficient and Specific Genome Editing. <i>Molecular Therapy</i> , 2015, 23, S132-S133.	8.2	4
30	Gene Editing with Crispr-Cas9 for Treating Beta-Hemoglobinopathies. <i>Blood</i> , 2015, 126, 3376-3376.	1.4	4
31	Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies. <i>Blood</i> , 2016, 128, 3623-3623.	1.4	3
32	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and Î²-Thalassemia. <i>Blood</i> , 2016, 128, 4708-4708.	1.4	2
33	Cellular Therapies: Gene Editing and Next-Gen CAR T Cells. , 2016, , 203-247.		1
34	Base Editors Flex Sights on Sickle-Cell Disease. <i>CRISPR Journal</i> , 2021, 4, 166-168.	2.9	0